Istesso – a London-based immunometabolism drug development company – has announced that the US Food and Drug Administration (FDA) has granted its ‘fast-track’ designation for Istesso’s investigational metabolic reprogramming agent, MBS2320
The therapy involves the treatment of patients with idiopathic pulmonary fibrosis (IPF).
The process is designed to facilitate the review of drugs to treat serious conditions and fill an unmet medical need. Meanwhile, the purpose is to get vital new drugs to the patient earlier. A fast-track treatment must show some advantages over existing therapies, such as the potential for superior effectiveness or an improved impact on serious outcomes.
